474 related articles for article (PubMed ID: 32164483)
1. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
Dees S; Pontiggia L; Jasmin JF; Mercier I
Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
[TBL] [Abstract][Full Text] [Related]
2. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
3. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
4. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
5. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
6. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
[TBL] [Abstract][Full Text] [Related]
7. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
[TBL] [Abstract][Full Text] [Related]
8. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
9. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
11. Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway.
Xie Q; Yang Z; Huang X; Zhang Z; Li J; Ju J; Zhang H; Ma J
J Hematol Oncol; 2019 Jun; 12(1):60. PubMed ID: 31186039
[TBL] [Abstract][Full Text] [Related]
12. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
[TBL] [Abstract][Full Text] [Related]
13. LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3.
Sharma U; Barwal TS; Khandelwal A; Malhotra A; Rana MK; Singh Rana AP; Imyanitov EN; Vasquez KM; Jain A
Biochimie; 2021 Mar; 182():99-107. PubMed ID: 33429003
[TBL] [Abstract][Full Text] [Related]
14. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
[TBL] [Abstract][Full Text] [Related]
15. Osthole inhibits triple negative breast cancer cells by suppressing STAT3.
Dai X; Yin C; Zhang Y; Guo G; Zhao C; Wang O; Xiang Y; Zhang X; Liang G
J Exp Clin Cancer Res; 2018 Dec; 37(1):322. PubMed ID: 30577812
[TBL] [Abstract][Full Text] [Related]
16. STAT3 Targets
Ma JH; Qi J; Lin SQ; Zhang CY; Liu FY; Xie WD; Li X
Mol Cancer Res; 2019 Nov; 17(11):2184-2195. PubMed ID: 31427441
[TBL] [Abstract][Full Text] [Related]
17. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
18. STAT3-induced NCK1 elevation promotes migration of triple-negative breast cancer cells via regulating ERK1/2 signaling.
He P; Sheng J; Qi J; Bai X; Li J; Wang F; Yuan Y; Zheng X
Mol Biol Rep; 2022 Jan; 49(1):267-278. PubMed ID: 34846647
[TBL] [Abstract][Full Text] [Related]
19. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
[TBL] [Abstract][Full Text] [Related]
20. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
